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INTRODUCTION
Acute viral hepatitis E, a self-limiting disease pre-
senting as acute, icteric hepatitis, is caused by hepa-
titis E virus (HEV). It is a small, non-enveloped RNA 
virus, icosahedral in shape, and 27-34 nm in dia-
metre (1). HEV is commonly transmitted through 
the faeco-oral route by contaminated water. Blood-
borne transmission and zoonotic reservoir of HEV 
have also been reported (2).
HEV has been responsible for major outbreaks of 
acute infection in developing countries of Asia, Af-
rica, and Latin America over the last 50 years. The 
first documented epidemic of HEV was reported in 
New Delhi, India, in 1955-1956, and 29,300 people 
were affected (3). Outbreaks have since been report-
ed from many countries of South and South-East 
Asia, Eastern Europe, and North and East Africa. 
The longest lasting outbreak was reported from 
South Xinjiang in Uighar region of China; the 
outbreak lasted for 20 months in 1986-1988. Over 
119,000 cases were reported (4) while the Kanpur 
outbreak of India in 1991 recorded over 79,000 
cases (5). Outbreaks of HEV usually coincide with 
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Acute hepatitis is seen sporadically round the year in Bangladesh. The incidence of acute viral hepatitis 
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heavy rains, resulting in flooding. This leads to sew-
age contamination of piped water through nearby 
sewerage lines or from contaminated surface-water. 
A similar outbreak was experienced in Dhaka city 
following the last major flooding in 2004. Almost 
80% of Bangladesh was under flood-water at that 
time for over a month. The outbreak affected over 
1,500 students of residential halls of the Univer-
sity of Dhaka (6). In the West and other developed 
countries, sporadic infections are seen in patients 
with a history of residence in or recent travel to en-
demic areas.
In the general population, HEV carries a low mor-
tality of 0.5-4% (7). However, this figure approaches 
>75% in developing countries, such as Bangladesh, 
in the second/third trimester of pregnancy and in 
patients with fulminant hepatic failure (7).
Detection of anti-HEV IgM still remains the main 
diagnostic marker of acute HEV infection (8). Anti-
HEV IgM appears in the serum of infected patients 
at the onset of symptoms, precedes appearance of 
anti-HEV IgG, and wanes within 2-5 months after 
infection (9). HEV’s RNA remains a more specific 
tool for the diagnosis of the infection; it, however, 
remains positive in serum for a short duration, and 
the test is also not commercially available. 
MATERIALS AND METHODS
                          HEV infection is common in Bangladesh. A previ-
ous study in Bangladesh has shown that the preva-
lence of anti-HEV IgM in our apparently-healthy 
population was 7.3% (10). In Pakistan, Hamid and 
colleagues from the Aga Khan Medical College in 
Karachi have reported a 17.5% prevalence of IgG to 
HEV in their population (11).
This is a retrospective study. Patients attending the 
Hepatology Unit III of the Bangabandhu Sheikh 
Mujib  Medical  University  (BSMMU)  during  June 
2004–December 2006 were included. All viral 
markers were tested by enzyme-linked immunosor-
bent assay (Abbott Labs, Chicago, USA). The viral 
markers that were tested included HBsAg, anti-
HBc IgM, and HBeAg for hepatitis B virus (HBV), 
anti-HEV IgM for HEV, anti-HAV IgM for hepati-
tis A virus (HAV), anti-HCV for hepatitis C virus 
(HCV), and anti-CMV for cytomegalovirus (CMV). 
In cirrhotics, HBV’s DNA was tested by polymerase 
chain reaction (PCR) (Taq Man PCR, Roche Mo-
lecular Systems, California, USA) having a lower 
limit of detection of 250 copies/mL. Serum biliru-
bin, transaminases, and albumin were tested using 
an autoanalyzer and prothrombin time by Quick’s 
method. Tests were done at the Departments of Bio-
chemistry, Hematology, and Virology of BSMMU 
maintaining high quality and assuring maximum 
possible accuracy of reports. 
The study had three main foci: (a) whether HEV 
attributes a major aetiologic fraction of clinical 
acute viral hepatitis, (b) if there is any association 
between hepatic/cirrhotic decompression and HEV 
infection in this region, and (c) the prognosis in pa-
tients with HEV-attributed FHF/ALF seen in these 
contexts.
The study population (n=267) was divided into four 
groups. Group 1 included 144 patients with acute 
viral hepatitis. The inclusion criteria were: prodro-
mal features, such as nausea and/or vomiting, loss 
of appetite, and serum bilirubin >200 µmol/L, 
raised serum transaminases, and prothrombin time 
>3 seconds prolonged beyond control value.
Group 2 included 31 pregnant women with acute 
viral hepatitis. All the patients had prodrome, icter-
us, raised serum bilirubin and raised serum trans-
aminase levels.
Group 3 included 23 patients presenting with ful-
minant hepatic failure. Patients were diagnosed 
based on the history from attendants, clinical fea-
tures, physical examinations, laboratory investiga-
tions, and imaging. Only those patients who pre-
sented with severe impairment of hepato-cellular 
function, i.e. encephalopathy, coagulopathy, and 
jaundice, within six months of onset of symptoms 
were included in the study. They were all previ-
ously healthy.
Finally, Group 4 had 69 patients with cirrhosis of 
liver. They presented with features of decompensa-
tion for the first time. The inclusion criteria were 
patients with established cirrhosis with jaundice 
and/or ascites with/without encephalopathy.
RESULTS
Of the 144 patients in Group 1, 58.33% (n=84) 
had acute viral E hepatitis, 31.25% (n=45) had 
acute viral B hepatitis, 4.86% (n=7) had acute viral 
A hepatitis, 2.78% (n=4) had mixed infection with 
both hepatitis E and A viruses, and 0.69% (n=1) had 
acute CMV hepatitis. Hepatitis was cryptogenic in 
the remaining 2.07% (n=3) of the 144 patients. 
In Group 2, of the 31 patients, 45.16% (n=14) had 
acute viral E hepatitis, 6.45% (n=2) had acute vi-
ral B hepatitis, and 9.38% (n=3) had mixed infec-
tion with both hepatitis E and B viruses. No virus Mahtab MA et al. Burden of HEV infection in Bangladesh
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marker could be detected in 38.71% (n=12) of the 
31 patients. Overall, 54.84% (n=17) of the 31 pa-
tients had HEV infection while 16.12% (n=5) had 
infection with HBV.
In Group 3, of the 23 patients, 56.52% (n=13) had 
HEV infection, 34.78% (n=8) had infection due 
to HBV, and 8.7% (n=2) had a history of intake of 
hepatotoxic drugs or alcohol abuse.
Finally, in Group 4, of the 69 patients, 21.7% (n=15) 
were anti-HEV IgM-positive, 4.3% (n=3) had a his-
tory of recent haemorrhage from the upper gastro-
intestinal tract, and 4.3% (n=3) had a history of 
intake of hepatotoxic drugs or alcohol abuse. No 
specific cause for decompensation of liver could be 
identified in the remaining 69.6% (n=48) of the 
patients. Decompensation in these cases probably 
resulted from the progression of cirrhosis.
Except for those included in Group 4, the patients 
had no pre-existing liver disease as revealed from 
their records. Patients belonging to Group 1 and 
Group 2 were conservatively managed and care-
fully followed up for the detection and manage-
ment of complications early.
In Group 2, the patients received conservative and 
supportive management with barrier nursing as 
far as practicable. Temperature and blood pressure 
were monitored at regular intervals, and an in-
put-output chart was maintained to avoid volume 
overload. Injection ceftriaxone was administered 
intravenously at a dose of 1 g twice daily to guard 
against infections, and continuous intravenous 
glucose infusion was given to prevent fatal hypo-
glycaemia. Intravenous cannula was replaced on 
every third day. Patients with features of bleeding 
received fresh frozen plasma transfusion. Fresh fro-
zen plasma transfusion was also given before and 
after labour or caesarian section.   
In Group 3, patients developed severe impairment 
of hepato-cellular function within less than six 
months of onset of their symptoms. This impair-
ment of liver function was evidenced by encepha-
lopathy, coagulopathy, and jaundice. The patients 
received conservative and supportive management 
with barrier nursing as far as practicable. Tempera-
ture and blood pressure were monitored at regular 
intervals, and an input-output chart was maintained 
to avoid volume overload. Nasogastric tube feeding 
and continuous catherization was constituted. In-
jection ceftriaxone was administered intravenously 
at a dose of 1 g twice daily to guard against infec-
tions, and continuous intravenous glucose infusion 
was given to prevent fatal hypoglycaemia. Intrave-
nous cannula was replaced on every third day. In-
travenous dopamine infusion was given to prevent 
hypotension and renal failure. In patients with 
features of hepato-renal syndrome, intravenous al-
bumin infusion and dopamine and nor-adrenaline 
drips were given. Patients with features of bleeding 
received fresh frozen plasma transfusion. Fresh fro-
zen plasma transfusion was also given before any 
invasive intervention. Intravenous mannitol was 
infused rapidly to prevent cerebral oedema in sus-
pected patients. 
In Group 4, patients were conservatively managed 
with antibiotics, non-selective beta-blocker, diu-
retics, albumin infusion, proton pump inhibitor, 
lactulose, vitamin K injection, and specific treat-
ment directed towards aetiology of cirrhosis. For 
instance, those with HBV-related cirrhosis received 
oral antivirals if they tested positive for HBV’s DNA 
by PCR.
Despite such measures, the outcome was generally 
fatal with high mortality recorded in patients in 
Group 2 and Group 3. HEV-related patients with 
fulminant hepatic failure had a mortality of 80%. 
Mortality was also 80% in the third trimester of 
pregnancy; however, none of the patients died, 
who were in their first or second trimester. The 
only factor that might have influenced HEV-related 
mortality in pregnancy appears to be the trimester 
of pregnancy, and other factors, such as age, socio-
economic background, or parity, had no effect.  
DISCUSSION
We observed that HEV was an important attributor 
to the aetiologic fraction of clinical acute viral hep-
atitis (Table). This observation is not different from 
other studies done in our region, namely in India, 
where HEV infection accounts for 50-70% of all 
cases of sporadic viral hepatitis (11,12). A group of 
researchers in India concluded from their study of 
76 pregnancies with acute hepatitis that HEV was 
the commonest cause (49.6%) (12). HBV, HAV, HCV, 
HDV, and non-A, non-E were responsible for 15%, 
1.5%, 1.7%, 1.5%, and 30.7% of cases respectively. 
They also found that, in the third trimester, HEV 
infection was associated with 22.2% of mortality 
compared to only 2.8% in non-pregnant women 
(13). Another Indian study also made similar ob-
servation. In their series of 62 pregnant patients, 
they found that 45.2% had HEV infection (14). 
The same researchers also found that HEV was res-
ponsible for 81% of cases with fulminant hepatic Mahtab MA et al. Burden of HEV infection in Bangladesh
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failure and 26.9% death cases in their patients (14). 
In Turkey, a study has shown that 12.6% (n=245) 
of acute hepatitis cases were HEV-related (15). 
We also identified HEV as a principal cause of ful-
minant hepatic failure/acute liver failur (ALF) in 
our study population (Table). Similar observation 
has been made in different studies done in our re-
gion. An earlier study in Bangladesh analyzed sera 
of 22 patients with fulminant hepatic failure (10). 
Anti-HEV IgM was detected in 63.6% and HBsAg 
in 35.7% of cases. Analysis of sera from 273 appar-
ently-healthy individuals revealed that 7.3% of the 
samples were positive for anti-HEV IgG. HEV infec-
tion was observed in 83.3% of HBV carriers (10). 
Researchers from India have studied 180 cases of 
fulminant hepatic failure to conclude that HEV is 
responsible for 43.9% of cases and HAV for 2.1%, 
HBV for 13.9%, HCV for 7.2%, and non-A, non-E 
agents for 31.1% of patients (16). Another study in 
India also revealed similar data showing that, of 102 
cases of fulminant hepatic failure, HEV remained 
the commonest aetiologic agent, followed by HBV, 
HAV, and HCV (17). A handful of cases were due to 
drugs and Wilson’s disease while no cause could be 
identified in 15 cases (17).  
Finally, we found the association between hepatic/
cirrhotic decompression and HEV infection (Table). 
In one of our works where we studied 139 patients 
with cirrhosis of liver, we found that HBV was the 
commonest cause of cirrhosis being responsible for 
61.15% of the cases, followed by HCV (30.94%) 
while 3.6% of the cases were cryptogenic, possibly 
reflecting occult HBV infection and non-alcoholic 
steato-hepatitis (NASH) (18). Results of other stud-
ies also showed that HEV was the leading cause of 
decompensation of liver in patients with cirrhosis 
in the developing world. In a study in India, 72 pa-
tients with recently-decompensated HBV-related 
cirrhosis of liver were included. Tests for hepatitis 
A to E, HBV DNA, and HIV-1 and HIV-2 were per-
formed (20). Extrinsic causes of decompensation 
were found in 35.6% of patients. It was observed 
that anti-HEV IgM was positive in 8.64%, anti-
HDV IgM in 10.17%, and anti-HAV IgM in 3.34% 
of patients while 3.34% were positive for both anti-
HDV IgM and anti HEV IgM. Intrinsic causes for 
decompensation, e.g. HBV reactivation and HCC, 
were found in 11.9% of patients, and 52.61% had 
neither any intrinsic nor extrinsic cause. It was, 
thus, concluded that HEV, followed by HDV, are 
the most common causes of decompensation of 
liver in cirrhotics in India (20). Another study in 
India included 10 patients with recently-decom-
pensated cirrhosis of liver (21). Of them, five had 
alcohol, two had HBV, and one had HCV as the 
aetiology for their cirrhosis. The remaining two 
were suffering from cryptogenic cirrhosis of liver. 
The patients were tested for HAV, HBV, HCV, and 
HEV. All the 10 patients tested positive for anti-
HEV IgM and negative for the remaining viruses 
(21). Researchers from North India shared similar 
experience. In their work, Arvind et al. studied 32 
patients with decompensated cirrhosis of liver, of 
whom 44% tested positive for anti-HEV IgM (22). 
On the contrary, anti-HEV IgM was positive in only 
6% of patients with compensated cirrhotics. They 
concluded that HEV is a frequent cause of decom-
pensation of cirrhotic liver (22).
Another study from Karachi, Pakistan, document-
ed four patients with recently-decompensated 
cirrhosis of liver, all of whom tested positive for 
anti-HEV IgM (11). The study found that anti-HEV 
IgG was positive in 17.5% of 233 patients with 
compensated cirrhosis, which is similar to 17.7% 
of healthy blood donors who also tested positive 
for anti-HEV IgG (11). A Nepalese study that re-
cruited 12 patients with decompensated cirrhosis 
of liver found that all of them tested positive for 
anti-HEV IgM (23). Of them, eight were alcoholic, 
Table. Burden of HEV-induced liver disease in 
Bangladesh
Acute hepatitis Results
HEV hepatitis in pregnant 
women (%)  58.33 (n=31)
HEV hepatitis in  
non-pregnant women (%) 45.16 (n=144)
Age (years) 8-82 (mean 32)
Male : female  
(non-pregnant) ratio 96:48
Mortality (pregnant: non-
pregnant) (%) 80:0
Fulminant hepatic failure
  HEV-related 56.52 (n=23)
  Age (years) 27-63 (mean 39)
  Male : female ratio 17:6
  Mortality (%) 80
Decompensation of cirrhosis
  HEV-related 21.7 (n=69)
  Age (years) 23-61 (mean 37)
  Male : female ratio 48:21
  Mortality (%) 5
HEV=Hepatitis E virusMahtab MA et al. Burden of HEV infection in Bangladesh
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one HBV-related, one HCV-related, one cardiac, 
one Budd Chiari-Syndrome, and one cryptogenic 
cirrhosis of liver (23). Finally, a very recent work 
in India, where 107 decompensated cirrhotics and 
200 controls were studied, found that HEV’s RNA 
was positive in 28% of cirrhotic patients compared 
to only 4.5% of controls (24). Seventy percent with 
and 27% without rapid decompensation had HEV 
infection. Mortality between HEV-infected and 
non-infected decompensated cirrhotic patients at 
four weeks (43% vs 22%) and at 12 months (70% 
vs 30%) was different (24).
Our study has certain limitations. It is a retrospec-
tive hospital-based study. Besides, although we had 
patients from all over the country, most of them 
came from around Dhaka. The sample size was also 
not large. The data are, therefore, referral-biased 
and allow only an insight into the clinical burden 
of HEV infections among the urban population of 
the capital city of Bangladesh. However, our find-
ings are similar to those reported by colleagues 
from our region.
Acute viral E hepatitis is an important cause of wide 
spectrum of clinically-presenting liver disease rang-
ing from severe acute viral hepatitis, fulminant he-
patic failure, to decompensation of liver in cirrhot-
ics in Bangladesh. Poor sanitation and hygienic 
conditions, lack of safe drinking-water supply, and 
overcrowding may all be responsible for the high 
prevalence of HEV infection. Besides, sewerage con-
tamination of piped water following floods may 
also contribute to the higher incidence of HEV in-
fection. Currently, there is no specific treatment for 
HEV infection. Treatment is supportive. Similarly, 
no vaccine against HEV is commercially available 
to date. Therefore, improvement of personal hy-
giene, ensuring supply of safe drinking-water, and, 
most importantly, raised public awareness remain 
important to guard against this virus for the time-
being. Keeping in mind the significant morbidity 
and also mortality associated with HEV infection 
in certain settings, this issue needs to be addressed 
with due importance, and physicians, NGOs, me-
dia, and political and community leaders should 
all discharge their respective responsibilities in this 
regard.
REFERENCES
1.  Margolis HS, Alter MJ, Halder SC. Viral hepatitis. In: 
Evans AS, Kaslow RA, editors. Viral infections of hu-
mans: epidemiology and control. 4th ed. New York, 
NY: Plenum Medical Book Company, 1997:363-406. 
2.  Favorov M, Nazarova O, Margolis HS. Is hepatitis E 
an emerging zoonotic disease? Presented at the Sec-
ond International Conference on Emerging Zoono-
ses, Strasbourg, France, November 5-9, 1998. (http://
epirev.oxfordjournals.org/cgi/reprint/21/2/162.pdf, 
accessed on 30 July 2008).
3.  Vishwanathan R. Infectious hepatitis in Delhi (1955-
56): a critical study. Epidemiology. Indian J Med Res 
1957;45:1-29.
4.  Zuang  H,  Cao  XY,  Liu  CB.  Enterically  tranmitted 
non-A, non-B hepatitis in China. In: Shikata T, Purcell 
RH, Uchida T, editors. Viral hepatitis C, D, and E: pro-
ceedings of the International Meeting on Non-A, Non-B 
Hepatitis. Amsterdam: Elsevier Science, 1991:275-85. 
5.  Ray R, Aggarwal R, Salunke PN, Mehrotra NN, Tal-
war GP, Naik SR. Hepatitis E virus genome in stools 
of hepatitis patients during large epidemic in north 
India. Lancet 1991;338:783-4.
6.  Mahtab MA, Khan M, Alam K, Rahman S, Ahmad N, 
Mamun AA et al. Hepatitis E virus is a leading cause of 
decompensation of liver in cirrhotic patients in Ban-
gladesh. Liver Int 2006;26:6.
7.  Krawczynski K. Hepatitis E. Hepatology 1993;17:932-
41.
8.  Clayson ET, Myint KS, Snitbhan R, Vaughn DW, In-
nis BL, Chan L et al. Viremia, fecal shedding, and IgM 
and IgG responses in patients with hepatitis E. J Infect 
Dis 1995;172:927-33.
9.  Bradley DW. Hepatitis E virus: a brief review of the 
biology, molecular virology, and immunology of a 
novel virus. J Hepatol 1995;22(Suppl 1):140-5.
10. Sheikh  A,  Sugitani  M,  Kinukawa  N,  Moriyama  M, 
Arakawa Y, Komiyama K et al. Hepatitis E virus infec-
tion in fulminant hepatitis patients and an apparent-
ly healthy population in Bangldesh. Am J Trop Med 
Hyg 2002;66:721-4.
11. Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa 
T, Salam A et al. Hepatitis E virus superinfection 
in patients with chronic liver disease. Hepatology 
2002;36:474-8.
12. Khuroo MS, Rustgi VK, Dawson GJ, Mushahwar IK, 
Yattoo GN, Kamili S et al. Spectrum of hepatitis E vi-
rus infection in India. J Med Virol 1994;43:281-6.
13. Khuroo MS, Duermeyer W, Zargar SA, Ahanger MA, 
Shah MA. Acute sporadic non-A, non-B hepatitis in 
India. Am J Epidemiol 1983;118:360-4.
14. Khuroo MS, Kamili S. Aetiology, clinical course and 
outcome of sporadic acute viral hepatitis in pregnan-
cy. J Viral Hep 2003;10:61-9. 
15. Kumar A, Beniwal M, Kar P, Sharma JB, Murthy 
NS. Hepatitis E in pregnancy. Int J Gynaecol Obstet 
2004;85:240-4.Mahtab MA et al. Burden of HEV infection in Bangladesh
Volume 27 | Number 1 | February 2009 19
16.  Khuroo MS, Kamili S. Aetiology and prognostic factors in 
acute liver failure in India. J Viral Hep 2003;10:224-31.
17. Bansal N, Sud R, Arora A, Kumar M, Saigal S, Puri R. 
Acute liver failure: aetiology, spectrum and predictors 
of survival on multivariate analysis. Indian J Gastroen-
terol 2005;24:116. 
18. Afroz S, Mahtab MA, Rahman S, Khan M. Hepatitis B 
virus is the leading cause of cirrhosis of liver in Ban-
gladesh. Hepatol Int 2007;1:120. 
19. Cevrioglu AS, Altindis M, Tanir HM, Aksoy F. Inves-
tigation of the incidence of hepatitis E virus among 
pregnant women in Turkey. J Obstet Gynaecol Res 
2004;30:48-52. 
20. Das K, Sharma BC, Sarin SK. Causes and profile 
of  acute  decompensation  in  hepatitis  B  related 
chronic liver disease in India. Indian J Gastroenterol 
2005;24:76.
21. Monga R, Garg S, Tyagi P, Kumar N. Superimposed 
acute hepatitis E infection in patients with chronic 
liver disease. Indian J Gastroenterol 2004;23:50-2. 
22. Kumar A, Aggarwal R, Naik SR, Saraswat V, Ghoshal 
UC, Naik S. Hepatitis E virus is responsible for decom-
pensation of chronic liver disease in an endemic re-
gion. Indian J Gastroenterol 2004;23:59-62.
23. Sudhamshu KC. Effects of hepatitis E virus infection 
in patients with chronic liver disease. J Gastroenterol 
Hepatol 2006;21:13. 
24. Kumar Acharya S, Kumar Sharma P, Singh R, Kumar 
Mohanty S, Madan K, Kumar Jha J et al. Hepatitis 
E virus (HEV) infection in patients with cirrhosis is 
associated with rapid decompensation and death. J 
Hepatol 2006;46:387-94.